Phase 1 Randomized Controlled Trial of the Safety and Immunogenicity of the SARS-CoV-2 (Omicron BA.5) mRNA-CR-04 Vaccine in Adults 18–49 Years of Age - Poll - MDSpire

Phase 1 Randomized Controlled Trial of the Safety and Immunogenicity of the SARS-CoV-2 (Omicron BA.5) mRNA-CR-04 Vaccine in Adults 18–49 Years of Age

  • By

  • Abdi Naficy

  • Mireille Venken

  • Yingmei Xi

  • Mark Loughrey

  • Giulietta Maruggi

  • Hema Sharma

  • Kunal Aggarwal

  • Daniel Brune

  • Bach-Yen Nguyen

  • November 26, 2025

  • 0 min

Share

Original Source(s)

Phase 1 Randomized Controlled Trial of the Safety and Immunogenicity of the SARS-CoV-2 (Omicron BA.5) mRNA-CR-04 Vaccine in Adults 18–49 Years of Age

  • by Abdi Naficy, Mireille Venken, Yingmei Xi, Mark Loughrey, Giulietta Maruggi, Hema Sharma, Kunal Aggarwal, Daniel Brune, Bach-Yen Nguyen

  • November 26, 2025

Related Content

Assessing the association of physical distancing to avoid COVID-19 with health-related quality of life in immunocompromised adolescents: results from the cross-sectional observational EAGLE study

MEK1/2 inhibitor ATR-002 reshapes host transcriptome and modulates immune regulatory genes in SARS-CoV-2 infection

Stewardship Cuts Steroid Prescribing

Behaviorally informed peer comparison feedback was associated with a gradual decline in glucocorticoid prescribing